2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Nombre del producto No. CAS Pureza Estructura química
  • HY-136111
    KR-26556 2411762-66-6 98%
    KR-26556 is a sulfonamide type hepatitis B virus (HBV) capsid assembly regulator. KR-26556 exhibits anti-HBV activity with an EC50 of 0.04 μM. KR-26556 has favorable safety characteristics. KR-26556 can be used for research on chronic hepatitis B.
    KR-26556
  • HY-13629S
    Etoposide-d3 98%
    Etoposide-d3 (VP-16-d3) is the deuterium labeled Etoposide (HY-13629). Etoposide (VP-16) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy.
    Etoposide-d3
  • HY-136348
    ML338 1630160-25-6 98%
    ML338 is a selective small molecule inhibitor probe of non-replicating Mycobacterium tuberculosis bacilli and is against the non-replicating M. tuberculosis with IC90 and IC99 values of 1 μM and 4 μM, respectively by CFU. ML338 is a invaluable tool for identifying both essential functions and vulnerabilities of the M. tuberculosis bacilli in the nutrient deprivation states. ML338 can be used for the study of M. tuberculosis chemotherapy.
    ML338
  • HY-13655A
    Isatoribine 122970-40-5 98%
    Isatoribine is a TLR7 agonist. Isatoribine is used in the study of chronic hepatitis C virus (HCV) infection.
    Isatoribine
  • HY-136752
    CYP51-IN-2 1155361-00-4 98%
    CYP51-IN-2 (compound 1b), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows 64 and 128 times higher activity than that of Fluconazole against Microsporum gypseum and Candida albicans, respectively.
    CYP51-IN-2
  • HY-136753
    Antifungal agent-162 1155361-01-5 98%
    Antifungal agent-162 (Compound 1c) is an Antifungal agent. Antifungal agent-162 exhibits potent in vitro antifungal activity against Candida albicans, Cryptococcus neoformans, Candida parapsilosis, Candida tropicalis, Candida krusei, and Microsporum gypseum (with MIC80 values ranging from 0.0156 to 0.25 μg/mL), while shows no activity against Aspergillus fumigatus.
    Antifungal agent-162
  • HY-136754
    CYP51-IN-4 1155361-02-6 98%
    CYP51-IN-2 (compound 1d), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 15.6 ng/mL for Microsporum gypseum and Candida albicans.
    CYP51-IN-4
  • HY-136755
    CYP51-IN-5 1155361-03-7 98%
    CYP51-IN-5 is a cytochrome P450 14α-demethylase (CYP51) inhibitor and an antifungal (fungal) agent belonging to the triazole derivative class. CYP51-IN-5 is applicable to the research of Candida albicans, Cryptococcus neoformans, Candida parapsilosis, Candida tropicalis, Trichophyton rubrum, Candida krusei and Microsporum gypseum.
    CYP51-IN-5
  • HY-136756
    CYP51-IN-6 1155361-04-8 98%
    CYP51-IN-2 (compound 1f), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 62.5 and 15.6 ng/mL for Microsporum gypseum and Candida albicans, respectively.
    CYP51-IN-6
  • HY-136757
    CYP51-IN-7 1155361-05-9 98%
    CYP51-IN-2 (compound 1g), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 62.5 and 250 ng/mL for Microsporum gypseum and Candida albicans, respectively.
    CYP51-IN-7
  • HY-136758
    CYP51-IN-8 1155361-06-0 98%
    CYP51-IN-2 (compound 1h), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 15.6 and 62.5 ng/mL for Microsporum gypseum and Candida albicans, respectively.
    CYP51-IN-8
  • HY-136759
    CYP51-IN-9 1155361-07-1 98%
    CYP51-IN-2 (compound 1i), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 62.5 for Microsporum gypseum and Candida albicans.
    CYP51-IN-9
  • HY-136760
    CYP51-IN-10 1155361-08-2 98%
    CYP51-IN-10 is cytochrome P450 14a-demethylase (CYP51) inhibitor with antifungal activity. CYP51-IN-10 can be used for the research of fungal infection.
    CYP51-IN-10
  • HY-136762
    CYP51-IN-12 1155361-10-6 98%
    CYP51-IN-2 (compound 1l), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 15.6 ng/mL for Microsporum gypseum and Candida albicans.
    CYP51-IN-12
  • HY-136763
    CYP51-IN-13 1155361-11-7 98%
    CYP51-IN-2 (compound 1m), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 62.5 and 250 ng/mL for Microsporum gypseum and Candida albicans, respectively.
    CYP51-IN-13
  • HY-136764
    CYP51-IN-14 1155361-12-8 98%
    CYP51-IN-2 (compound 1n), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 1 μg/mL for Microsporum gypseum and Candida albicans.
    CYP51-IN-14
  • HY-136783
    G6PD-IN-2 333311-00-5 98%
    G6PD-IN-2 is a Plasmodium falciparum glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 value of 0.2 μM. G6PD-IN-2 exerts weak inhibitory activity on Plasmodium falciparum glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase (PfGluPho) with an IC50 value of 22.0 μM. G6PD-IN-2 inhibits growth of Plasmodium falciparum 3D7 strain and exhibits low cytotoxicity in hepatocytes. G6PD-IN-2 can be used for the research of malaria.
    G6PD-IN-2
  • HY-136821
    Polymyxin D2 34167-45-8 98%
    Polymyxin D2 is an antibiotic discovered from Bacillus polymyxa, exhibiting antibacterial activity. Its core structure consists of a cyclic heptapeptide moiety and a tripeptide side chain with a fatty acyl residue. Polymyxin D2 can be used in anti-infective research.
    Polymyxin D2
  • HY-136885
    (S,S)-TAPI-0 143457-40-3 98%
    (S,S)-TAPI-0 is a matrix metalloproteinase (MMP) inhibitor that inhibits the growth of Chlamydia trachomatis by inhibiting PDF enzyme activity. (S,S)-TAPI-0 can be used to study Chlamydia infection.
    (S,S)-TAPI-0
  • HY-136926
    Candicidin A3 58591-23-4 98%
    Candicidin A3 (FR-008I) is an antifungal antibiotic with significant biological activity. Candicidin A3 can effectively inhibit the growth of fungi through its unique three-dimensional structure and seven-membered ring geometry. The absolute configuration of Candicidin A3 is a specific arrangement of multiple chiral centers, which may affect its biological activity and interaction with targets. Candicidin A3 can be used as a potential drug to inhibit fungal infections.
    Candicidin A3
Cat. No. Nombre del producto / Synonyms Application Reactivity